| Detected | Trial | Change |
|---|---|---|
| 2026-06-02 | NCT06003231 A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 |
date change Primary completion moved earlier: 2026-05-31 -> 2026-03-27 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-05-27 | NCT07608224 HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable… | Phase 2/3 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07315750 | A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus… | Gastric Carcinoma | Recruiting |
| NCT05911295 | Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial… | Urothelial Carcinoma | Active, Not Recruiting |
| Phase 2/3 | |||
| NCT07366840 | RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With… | HER2-positive Breast Cancer | Not Yet Recruiting |
| NCT07608224 | HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable… | Urinary Bladder Neoplasms | Not Yet Recruiting |
| Phase 2 | |||
| NCT07446452 | Disitamab Vedotin Plus Bevacizumab in HER2-Low Metastatic Breast Cancer After T-DXd… | HER2-low Breast Cancer | Recruiting |
| NCT07474324 | Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for… | GC/GEJC | Recruiting |
| NCT04879329 | A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That… | Urothelial Carcinoma | Recruiting |
| NCT06157892 | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | Breast Neoplasms | Recruiting |
| NCT07474064 | Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving… | Muscle Invasive Bladder Cancer (MIBC) | Not Yet Recruiting |
| NCT07498907 | Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing… | Upper Tract Urothelial Carcinoma | Not Yet Recruiting |
| NCT06003231 | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | Carcinoma, Non-Small-Cell Lung | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06966453 | A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | Breast Cancer | Recruiting |
| Not specified | |||
| NCT05831878 | RC48-ADC in HER2-low Advanced Breast Cancer | Advanced Breast Cancer | Recruiting |